Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 4/20 | 0.41 |
| ▸ | SPR | P35270 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | PNPLA2 | Q96AD5 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | CCR2 | P41597 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7081133 | 0.89 | NR3C1 (0.44) | POLBSPRMAPTKDM4EPDE4D | |
| SCHEMBL7078063 | 0.87 | SPR (0.40) | POLBSPRMAPTKDM4EPDE4D | |
| SCHEMBL7079006 | 0.87 | MEN1 (0.45) | POLBSPRMAPTRXFP1CCR2 | |
| SCHEMBL7075366 | 0.86 | PDE4A (0.49) | POLBSPRMAPTNPSR1PDE4D | |
| SCHEMBL5961440 | 0.85 | TP53 (0.47) | POLBMAPTCCR2CCR5NR3C1 | |
| SCHEMBL5961572 | 0.84 | CCR2 (0.49) | POLBSPRMAPTPDE4DPDE4A | |
| SCHEMBL7079264 | 0.83 | NR3C1 (0.40) | POLBSPRCCR2CCR5NR3C1 | |
| SCHEMBL7074009 | 0.83 | NR3C1 (0.48) | POLBSPRCCR2CCR5NR3C1 | |
| SCHEMBL7077952 | 0.83 | SPR (0.48) | POLBSPRCCR2CCR5NR3C1 | |
| SCHEMBL7137484 | 0.82 | SPR (0.43) | POLBSPRMAPTCCR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670364-B2 | For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases | TELIK, INC. | 2003-12-30 | — | — | US | claimed |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | POLB 3248/4885SPR 430/4885MAPK14 2021/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.